Author:
Boisclair Stephanie,Zhou Edward,Naing Phyu,Thakur Richa,Jou Erin,Goldberg Bradley,Gladstone Douglas E.,Allen Steven L.,Kolitz Jonathan E.,Chitty David W.
Reference27 articles.
1. De novo acute myeloid leukemia: a population- based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017;Sasaki;Cancer,2021
2. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia;Fernandez;Blood,2021
3. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study;Al-Ali;Leuk. Lymphoma,2012
4. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia;Kantarjian;J. Clin. Oncol. J. Am. Soc. Clin. Oncol.,2012
5. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia;Ritchie;Leuk. Lymphoma,2013
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献